English
Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule
Anti-BCMA-Anti-CD19-Anti-CD3 Trispecific Molecule
Artikelnummer
BPS100761-2
Verpackungseinheit
100 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti CD19-anti-CD3 can be used for studying BCMA+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lin
Background: B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. Upregulation of BCMA also correlates with disease burden and prognosis in multiple myeloma.B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies.
Description: The Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody is engineered to bind to three different targets simultaneously: 1) BCMA, a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells, 2) CD19, a B-cell marker that is a target for many leukemias and lymphomas, and 3) CD3, a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific antibody allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Purification: His-tag affinity purification from HEK293 cells
Purity: 0,88
Storage Stability: Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles.
Supplied As: Aqueous buffer solution.
Tags: N-terminal His-tag
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
Applications: This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti CD19-anti-CD3 can be used for studying BCMA+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lin
Background: B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. Upregulation of BCMA also correlates with disease burden and prognosis in multiple myeloma.B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies.
Description: The Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody is engineered to bind to three different targets simultaneously: 1) BCMA, a B cell antigen that is highly expressed by mature B cells and malignant myeloma cells, 2) CD19, a B-cell marker that is a target for many leukemias and lymphomas, and 3) CD3, a T cell receptor activation signal that leads to cytokine secretion. The multi-functionality of this trispecific antibody allows it to bind to BCMA and CD19 on the tumor cell and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event targets the tumor while providing co-stimulatory signals that promote T cell expansion and cytotoxicity against BCMA+ and CD19+ cancer cells.
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Purification: His-tag affinity purification from HEK293 cells
Purity: 0,88
Storage Stability: Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles.
Supplied As: Aqueous buffer solution.
Tags: N-terminal His-tag
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS100761-2 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 100761-2 |
| Green Labware | Nein |
| Verpackungseinheit | 100 µg |
| Mengeneinheit | STK |
| Klonalität | Monoclonal |
| Isotyp | BiTE variable regions only |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
